Clinical trial
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT05306340 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- August 3, 2022
- Completion date
- October 15, 2026
- Enrollment
- 373 (actual)
- Sites
- 136
Conditions
As the registry lists them; a condition with its own page is linked.
estrogen receptor (er)-positive, her2-negative, locally advanced or metastatic breast cancer